The Supreme Court's decision in Myriad highlights the need for tools enabling nuanced and precise analysis of gene patents at the global level.
No takes yet. Share an insight, caveat, or question.
Jefferson et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: